WORLD PEPTIDEFOUNDATION

Where is GHRP-2 being studied?

Find registered human studies, phases, products, recruitment status and reported research locations around the world. Registry search matches are separate from this profile’s reviewed evidence.

Find studies for GHRP-2 →Worldwide registry directory

Scientific intelligence record

Experience 2.0

Growth hormone secretagogue peptide

GHRP-2

Synthetic growth-hormone secretagogue and ghrelin-receptor agonist studied in endocrine challenge testing.

Record status

Traceability partial

Last meaningful update: 9/20/2026

Evidence searched through:
Not recorded
Assessment updated:
9/20/2026
Documented human review:
No documented human review recorded
Automated scientific assessment:
None recorded
AI source check:
9/26/2026

Published source links and profile text pass separate gates. Only a documented human review is labelled as human review; an automated scientific assessment applies deterministic checks, and an AI source check confirms only that a source exists and matches its identifiers. A source count alone does not establish a review.

Evidence coverage has three distinct layers. The corpus count is a transparent screening inventory, the featured set contains study-level tiering and interpretation, and the published-source count contains records promoted through the institutional publication workflow. Source validation, editorial publication, and scientific appraisal are separate decisions; these numbers must not be merged.

Ranked research corpus

269

Categorized publications with provisional ranking; scientific review remains separate.

Featured tiered studies

0

Cornerstone publications with study-level interpretation, limitations, and tier disclosure.

Research domains

6

Clinical and scientific questions synthesized independently across the evidence atlas.

Published source records

26

Database records promoted through the governed publication workflow—not the corpus total.

Corpus generated 2026-09-18. Counts remain separately labeled so screening is not represented as completed review.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observationArchive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Ranked research corpus

269

Categorized screening records; proposed rankings remain pending human appraisal.

Featured tiered studies

0

Cornerstone studies with published study-level interpretation and tier disclosure.

Research domains

6

Independent evidence dossiers covering the major research questions.

Published source records

26

Source records published through the governed workflow; this count does not certify scientific conclusions.

Contradictions

0

Conflicting evidence relationships that remain visible.

Research gaps

1

Questions the current record identifies as unresolved.

Connected media

0

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

6 published domain syntheses connected to 0 featured studies

GHRP-2 no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded synthesis, confidence level, evidence context, limitations, geographic applicability, regulatory interpretation, and research gaps. Publication of these syntheses is separate from the scientific review status shown above.

Inspect the reconciled evidence atlas
Inspect the published evidence record26 governed records · titles, provenance, and original-source linksOpen records ↓
2007Phase 1–2 human evidence

A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency.

PubMed-indexed controlled clinical trial; journal article; research support, non-u.s. gov't; validation study examining a simple diagnostic test using gh-releasing peptide-2 in adult gh deficiency. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Kazuo Chihara; Akira Shimatsu; Naomi Hizuka; Toshiaki Tanaka; Yoshiki Seino; Yuzuru Katofor; KP-102 Study Group
Source
European journal of endocrinology
DOI
10.1530/EJE-07-0066
PubMed
17609397
Open original source
1996Phase 1–2 human evidence

Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.

PubMed-indexed clinical trial; comparative study; journal article; randomized controlled trial; research support, non-u.s. gov't examining pituitary responsiveness to gh-releasing hormone, gh-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
G Van den Berghe; F de Zegher; C Y Bowers; P Wouters; P Muller; F Soetens; D Vlasselaers; M Schetz; C Verwaest; P Lauwers; R Bouillon
Source
Clinical endocrinology
DOI
10.1046/j.1365-2265.1996.00805.x
PubMed
8949573
Open original source
2004Observational human evidence

Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN.

PubMed-indexed journal article; review examining pralmorelin: ghrp 2, gpa 748, growth hormone-releasing peptide 2, kp-102 d, kp-102 ln, kp-102d, kp-102ln. Machine-staged source candidate; findings and limitations require accountable review before publication.

Source
Drugs in R&D
DOI
10.2165/00126839-200405040-00011
PubMed
15230633
Open original source
2004Observational human evidence

Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.

PubMed-indexed journal article examining pharmacological characteristics of kp-102 (ghrp-2), a potent growth hormone-releasing peptide. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Naomi Doi; Chiharu Hirotani; Kiyoharu Ukai; Osafumi Shimada; Tadashi Okuno; Shigeru Kurasaki; Takeshi Kiyofuji; Reiko Ikegami; Machiko Futamata; Terutake Nakagawa; Katsuhiko Ase; Kazuo Chihara
Source
Arzneimittel-Forschung
DOI
10.1055/s-0031-1297041
PubMed
15646370
Open original source
1993Observational human evidence

GH releasing peptides--structure and kinetics.

PubMed-indexed comparative study; journal article; research support, u.s. gov't, p.h.s. examining gh releasing peptides--structure and kinetics. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
C Y Bowers
Source
The Journal of pediatric endocrinology
DOI
10.1515/jpem.1993.6.1.21
PubMed
8374685
Open original source
2019Observational human evidence

Glycine-modified growth hormone secretagogues identified in seized doping material.

PubMed-indexed journal article examining glycine-modified growth hormone secretagogues identified in seized doping material. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Paulina Marta Gajda; Niels Bjerre Holm; Lars Jakobsen Hoej; Brian Schou Rasmussen; Petur Weihe Dalsgaard; Lotte Ask Reitzel; Kristian Linnet
Source
Drug testing and analysis
DOI
10.1002/dta.2489
PubMed
30136411
Open original source
2018Observational human evidence

Analysis of new growth promoting black market products.

PubMed-indexed journal article; research support, non-u.s. gov't examining analysis of new growth promoting black market products. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Oliver Krug; Andreas Thomas; Helle Malerød-Fjeld; Yvette Dehnes; Tim Laussmann; Ingo Feldmann; Albert Sickmann; Mario Thevis
Source
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
DOI
10.1016/j.ghir.2018.05.001
PubMed
29864719
Open original source
2018Observational human evidence

Evaluation of growth hormone-releasing peptide-2 for diagnosis of thyrotropin-producing pituitary adenomas.

PubMed-indexed journal article examining evaluation of growth hormone-releasing peptide-2 for diagnosis of thyrotropin-producing pituitary adenomas. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Kazunori Kageyama; Satoru Sakihara; Wataru Kameda; Aya Sugiyama; Shinobu Takayasu; Ken Terui; Makoto Daimon
Source
Endocrine journal
DOI
10.1507/endocrj.EJ17-0527
PubMed
29973439
Open original source
2019Observational human evidence

Detection of black market follistatin 344.

PubMed-indexed journal article examining detection of black market follistatin 344. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Christian Reichel; Günter Gmeiner; Mario Thevis
Source
Drug testing and analysis
DOI
10.1002/dta.2741
PubMed
31758732
Open original source
2005Observational human evidence

Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men.

PubMed-indexed journal article; research support, u.s. gov't, p.h.s. examining growth hormone releasing peptide-2 (ghrp-2), like ghrelin, increases food intake in healthy men. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Blandine Laferrère; Cynthia Abraham; Colleen D Russell; Cyril Y Bowers
Source
The Journal of clinical endocrinology and metabolism
DOI
10.1210/jc.2004-1719
PubMed
15699539
Open original source
2014Observational human evidence

Intraportal infusion of ghrelin could inhibit glucose-stimulated GLP-1 secretion by enteric neural net in Wistar rat.

PubMed-indexed journal article; research support, non-u.s. gov't examining intraportal infusion of ghrelin could inhibit glucose-stimulated glp-1 secretion by enteric neural net in wistar rat. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Xiyao Zhang; Wensong Li; Ping Li; Manli Chang; Xu Huang; Qiang Li; Can Cui
Source
BioMed research international
DOI
10.1155/2014/923564
PubMed
25247193
Open original source
2000Observational human evidence

The hexapeptide KP-102 (D-ala-D-beta-Nal-ala-trp-D-phe-lys-NH(2)) stimulates growth hormone release in a cichlid fish (Ooreochromis mossambicus).

PubMed-indexed journal article; research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s. examining the hexapeptide kp-102 (d-ala-d-beta-nal-ala-trp-d-phe-lys-nh(2)) stimulates growth hormone release in a cichlid fish (ooreochromis mossambicus). Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
B S Shepherd; S M Eckert; I S Parhar; M M Vijayan; I Wakabayashi; T Hirano; E G Grau; T T Chen
Source
The Journal of endocrinology
DOI
10.1677/joe.0.167r007
PubMed
11115782
Open original source
1997Observational human evidence

Growth hormone-releasing peptides.

PubMed-indexed journal article; research support, non-u.s. gov't; review examining growth hormone-releasing peptides. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
E Ghigo; E Arvat; G Muccioli; F Camanni
Source
European journal of endocrinology
DOI
10.1530/eje.0.1360445
PubMed
9186261
Open original source
1998Observational human evidence

Ipamorelin, the first selective growth hormone secretagogue.

PubMed-indexed journal article examining ipamorelin, the first selective growth hormone secretagogue. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
K Raun; B S Hansen; N L Johansen; H Thøgersen; K Madsen; M Ankersen; P H Andersen
Source
European journal of endocrinology
DOI
10.1530/eje.0.1390552
PubMed
9849822
Open original source
2017Observational human evidence

Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.

PubMed-indexed journal article examining growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
John T Sigalos; Alexander W Pastuszak; Andrew Allison; Samuel J Ohlander; Amin Herati; Mark C Lindgren; Larry I Lipshultz
Source
American journal of men's health
DOI
10.1385/endo:22:1:25
PubMed
28830317
Open original source
2022Observational human evidence

Association between overweight and growth hormone secretion in patients with non-functioning pituitary tumors.

PubMed-indexed journal article; research support, non-u.s. gov't examining association between overweight and growth hormone secretion in patients with non-functioning pituitary tumors. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Yasufumi Seki; Atsuhiro Ichihara
Source
PloS one
DOI
10.1210/jcem.77.3.8103770
PubMed
35452483
Open original source
2017Observational human evidence

Structure-activity relationship for peptídic growth hormone secretagogues.

PubMed-indexed journal article examining structure-activity relationship for peptídic growth hormone secretagogues. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
P Ferro; G Krotov; I Zvereva; G Rodchenkov; J Segura
Source
Drug testing and analysis
DOI
10.1002/dta.1947
PubMed
26811125
Open original source
2015Observational human evidence

Synthesis of Mono-PEGylated Growth Hormone Releasing Peptide-2 and Investigation of its Biological Activity.

PubMed-indexed journal article examining synthesis of mono-pegylated growth hormone releasing peptide-2 and investigation of its biological activity. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Xiaoyu Hu; Beihua Xu; Ziniu Zhou
Source
AAPS PharmSciTech
DOI
10.1007/s12272-010-0718-z
PubMed
25761386
Open original source
2020Observational human evidence

Determination of the immunostimulatory drug-glucosoaminyl-muramyl-dipeptide-in human plasma using HPLC-MS/MS and its application to a pharmacokinetic study.

PubMed-indexed journal article examining determination of the immunostimulatory drug-glucosoaminyl-muramyl-dipeptide-in human plasma using hplc-ms/ms and its application to a pharmacokinetic study. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Natalia E Moskaleva; Pavel A Markin; Roman M Kuznetsov; Tatiana M Andronova; Svetlana A Appolonova
Source
Biomedical chromatography : BMC
DOI
10.1002/bmc.4948
PubMed
32652605
Open original source
2004Observational human evidence

General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.

PubMed-indexed journal article examining general pharmacology of kp-102 (ghrp-2), a potent growth hormone-releasing peptide. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Sadayoshi Furuta; Osafumi Shimada; Naomi Doi; Kiyoharu Ukai; Terutake Nakagawa; Jyo Watanabe; Masakazu Imaizumi
Source
Arzneimittel-Forschung
DOI
10.1055/s-0031-1297042
PubMed
15646371
Open original source
2012Observational human evidence

Metabolism of growth hormone releasing peptides.

PubMed-indexed journal article; research support, non-u.s. gov't examining metabolism of growth hormone releasing peptides. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Andreas Thomas; Philippe Delahaut; Oliver Krug; Wilhelm Schänzer; Mario Thevis
Source
Analytical chemistry
DOI
10.1021/ac302034w
PubMed
23101768
Open original source
2006Animal research

KP-102 (growth hormone-releasing peptide-2) attenuates ischemia/reperfusion injury in isolated rat hearts.

PubMed-indexed journal article examining kp-102 (growth hormone-releasing peptide-2) attenuates ischemia/reperfusion injury in isolated rat hearts. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Sadayoshi Furuta; Toshimitsu Hori; Tadashi Ohyama
Source
Naunyn-Schmiedeberg's archives of pharmacology
DOI
10.1007/s00210-006-0079-9
PubMed
16773386
Open original source
2005Animal research

ACTH releasing activity of KP-102 (GHRP-2) in rats is mediated mainly by release of CRF.

PubMed-indexed journal article examining acth releasing activity of kp-102 (ghrp-2) in rats is mediated mainly by release of crf. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Chiharu Hirotani; Yutaka Oki; Kiyoharu Ukai; Tadashi Okuno; Shigeru Kurasaki; Tadashi Ohyama; Naomi Doi; Ken Sasaki; Katsuhiko Ase
Source
Naunyn-Schmiedeberg's archives of pharmacology
DOI
10.1007/s00210-004-1009-3
PubMed
15645295
Open original source
2009Animal research

Growth hormone-releasing peptide-2 stimulates secretion and synthesis of adrenocorticotropic hormone in mouse pituitary.

PubMed-indexed journal article; research support, non-u.s. gov't examining growth hormone-releasing peptide-2 stimulates secretion and synthesis of adrenocorticotropic hormone in mouse pituitary. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Kazunori Kageyama; Mihoko Kushibiki; Komaki Hanada; Satoru Sakihara; Minoru Yasujima; Toshihiro Suda
Source
Regulatory peptides
DOI
10.1016/j.regpep.2009.07.018
PubMed
19682503
Open original source
2016Laboratory research

Growth Hormone Releasing Peptide-2 Attenuation of Protein Kinase C-Induced Inflammation in Human Ovarian Granulosa Cells.

PubMed-indexed journal article examining growth hormone releasing peptide-2 attenuation of protein kinase c-induced inflammation in human ovarian granulosa cells. Machine-staged source candidate; findings and limitations require accountable review before publication.

Authors
Yi-Ning Chao; David Sun; Yen-Chun Peng; Yuh-Lin Wu
Source
International journal of molecular sciences
DOI
10.1074/jbc.270.42.24965
PubMed
27548147
Open original source
Insufficient evidence

Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.

Source reference associated with GHRP-2. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.21037/tau.2019.11.30
PubMed
32257855
Open original source

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓
Chemical identity

Molecular and structural record

Structured record
Molecular formula
C45H55N9O6
Molecular weight (Da)
818
InChIKey
HRNLPPBUBKMZMT-RDRUQFPZSA-N

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Research discovery

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

  1. 1993 · study · Temporal status not established

    GH releasing peptides--structure and kinetics.

    The Journal of pediatric endocrinology

  2. 1996 · study · Temporal status not established

    Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.

    Clinical endocrinology

  3. 1997 · study · Temporal status not established

    Growth hormone-releasing peptides.

    European journal of endocrinology

  4. 1998 · study · Temporal status not established

    Ipamorelin, the first selective growth hormone secretagogue.

    European journal of endocrinology

  5. 2000 · study · Temporal status not established

    The hexapeptide KP-102 (D-ala-D-beta-Nal-ala-trp-D-phe-lys-NH(2)) stimulates growth hormone release in a cichlid fish (Ooreochromis mossambicus).

    The Journal of endocrinology

  6. 2004 · study · Temporal status not established

    Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN.

    Drugs in R&D

  7. 2004 · study · Temporal status not established

    Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.

    Arzneimittel-Forschung

  8. 2004 · study · Temporal status not established

    General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide.

    Arzneimittel-Forschung

  9. 2005 · study · Temporal status not established

    Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men.

    The Journal of clinical endocrinology and metabolism

  10. 2005 · study · Temporal status not established

    ACTH releasing activity of KP-102 (GHRP-2) in rats is mediated mainly by release of CRF.

    Naunyn-Schmiedeberg's archives of pharmacology

  11. 2006 · study · Temporal status not established

    KP-102 (growth hormone-releasing peptide-2) attenuates ischemia/reperfusion injury in isolated rat hearts.

    Naunyn-Schmiedeberg's archives of pharmacology

  12. 2007 · study · Temporal status not established

    A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency.

    European journal of endocrinology

  13. 2009 · study · Temporal status not established

    Growth hormone-releasing peptide-2 stimulates secretion and synthesis of adrenocorticotropic hormone in mouse pituitary.

    Regulatory peptides

  14. 2012 · study · Temporal status not established

    Metabolism of growth hormone releasing peptides.

    Analytical chemistry

  15. 2014 · study · Temporal status not established

    Intraportal infusion of ghrelin could inhibit glucose-stimulated GLP-1 secretion by enteric neural net in Wistar rat.

    BioMed research international

  16. 2015 · study · Temporal status not established

    Synthesis of Mono-PEGylated Growth Hormone Releasing Peptide-2 and Investigation of its Biological Activity.

    AAPS PharmSciTech

  17. 2016 · study · Temporal status not established

    Growth Hormone Releasing Peptide-2 Attenuation of Protein Kinase C-Induced Inflammation in Human Ovarian Granulosa Cells.

    International journal of molecular sciences

  18. 2017 · study · Temporal status not established

    Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.

    American journal of men's health

  19. 2017 · study · Temporal status not established

    Structure-activity relationship for peptídic growth hormone secretagogues.

    Drug testing and analysis

  20. 2018 · study · Temporal status not established

    Analysis of new growth promoting black market products.

    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society

  21. 2018 · study · Temporal status not established

    Evaluation of growth hormone-releasing peptide-2 for diagnosis of thyrotropin-producing pituitary adenomas.

    Endocrine journal

  22. 2019 · study · Temporal status not established

    Glycine-modified growth hormone secretagogues identified in seized doping material.

    Drug testing and analysis

  23. 2019 · study · Temporal status not established

    Detection of black market follistatin 344.

    Drug testing and analysis

  24. 2020 · study · Temporal status not established

    Determination of the immunostimulatory drug-glucosoaminyl-muramyl-dipeptide-in human plasma using HPLC-MS/MS and its application to a pharmacokinetic study.

    Biomedical chromatography : BMC

  25. 2022 · study · Temporal status not established

    Association between overweight and growth hormone secretion in patients with non-functioning pituitary tumors.

    PloS one

  26. 2026 · regulatory · Temporal status not established

    Regulatory review: not_approved

    European Union

  27. 2026 · regulatory · Temporal status not established

    Regulatory review: not_approved

    United States

  28. Date unavailable · study · Temporal status not established

    Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.

    other

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Claim traceability

No institutional claim record is currently represented for this peptide.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Researchers represented in the evidence record12 bibliographic identities · open to inspect

These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.

Mario Thevis

3 represented evidence records

Years represented: 2012, 2018, 2019

Publishing organizations appearing in records: Analytical chemistry, Drug testing and analysis, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society

Andreas Thomas

2 represented evidence records

Years represented: 2012, 2018

Publishing organizations appearing in records: Analytical chemistry, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society

C Y Bowers

2 represented evidence records

Years represented: 1993, 1996

Publishing organizations appearing in records: Clinical endocrinology, The Journal of pediatric endocrinology

Chiharu Hirotani

2 represented evidence records

Years represented: 2004, 2005

Publishing organizations appearing in records: Arzneimittel-Forschung, Naunyn-Schmiedeberg's archives of pharmacology

Katsuhiko Ase

2 represented evidence records

Years represented: 2004, 2005

Publishing organizations appearing in records: Arzneimittel-Forschung, Naunyn-Schmiedeberg's archives of pharmacology

Kazunori Kageyama

2 represented evidence records

Years represented: 2009, 2018

Publishing organizations appearing in records: Endocrine journal, Regulatory peptides

Kazuo Chihara

2 represented evidence records

Years represented: 2004, 2007

Publishing organizations appearing in records: Arzneimittel-Forschung, European journal of endocrinology

Kiyoharu Ukai

3 represented evidence records

Years represented: 2004, 2005

Publishing organizations appearing in records: Arzneimittel-Forschung, Naunyn-Schmiedeberg's archives of pharmacology

Naomi Doi

3 represented evidence records

Years represented: 2004, 2005

Publishing organizations appearing in records: Arzneimittel-Forschung, Naunyn-Schmiedeberg's archives of pharmacology

Oliver Krug

2 represented evidence records

Years represented: 2012, 2018

Publishing organizations appearing in records: Analytical chemistry, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society

Sadayoshi Furuta

2 represented evidence records

Years represented: 2004, 2006

Publishing organizations appearing in records: Arzneimittel-Forschung, Naunyn-Schmiedeberg's archives of pharmacology

Satoru Sakihara

2 represented evidence records

Years represented: 2009, 2018

Publishing organizations appearing in records: Endocrine journal, Regulatory peptides

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Open 12 represented connections ↓

institution

European journal of endocrinology

represented evidence source

institution

Drug testing and analysis

represented evidence source

institution

Arzneimittel-Forschung

represented evidence source

institution

Naunyn-Schmiedeberg's archives of pharmacology

represented evidence source

institution

Clinical endocrinology

represented evidence source

institution

Drugs in R&D

represented evidence source

institution

The Journal of pediatric endocrinology

represented evidence source

institution

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society

represented evidence source

institution

Endocrine journal

represented evidence source

institution

The Journal of clinical endocrinology and metabolism

represented evidence source

institution

BioMed research international

represented evidence source

institution

The Journal of endocrinology

represented evidence source

Traceability

Follow the record back to its source

The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.

Source publication state

A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Domain conclusion → Evidence

Connected

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Reconciled for 6 domain conclusions and 0 featured studies.

Detailed study-to-domain mappings and original-source paths appear in the GHRP-2 evidence-governance section.

Inspect the ranked source records

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Regulatory context

Published jurisdictional records

Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.

European Union

Regulator: Not represented

not_approved

As of: 9/9/2026 · Temporal status not established

Regulatory context incomplete: regulator.

EMA medicines portal

United States

Regulator: Not represented

not_approved

As of: 9/9/2026 · Temporal status not established

Regulatory context incomplete: regulator.

FDA Drugs@FDA / official FDA record

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.
Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.
Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.
Contradictory and qualifying evidence must remain visible rather than being silently discarded.
Absence of represented evidence is not evidence that research does not exist.
Research gaps identify unresolved questions; they are not negative conclusions.
Regulatory status is distinct from scientific evidence quality.
Media relationships provide context and explanation; they do not increase the strength of scientific evidence.
A section with no represented records is an incomplete project record, not a scientific conclusion.
Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.

Generated: 11/8/2026, 5:24:50 PM

global evidence atlas

GHRP-2 research, ranked and separated by purpose

This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

269Discoverable source universe
269Ranked screening records
6Research domains
0Accountably approved conclusions

269 matching records · ranked 2026-09-18

Page 1 of 11

Count reconciliation: 269 discoverable source records match the peptide identity query; 269 are retained in this bounded, ranked screening view; 0 belong to the separate governed layer labeled “Accountably approved conclusions.” Domain totals overlap because one publication may inform several questions.

governance and regulatory context

GHRP-2: what this atlas does and does not establish

Last checked
2026-09-18
Accountable publication approval
Not yet approved by a named accountable reviewer. Machine screening only.

No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.

Regulatory status by jurisdiction

Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.

Known limitations of this pass

  • no patent candidate retained after literal filter

No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review. 2 correction(s) have been recorded against this atlas's source metadata.

GHRP-2 evidence · ranking key

How evidence is ranked

A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.

A

Practice-defining evidence

Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.

B

Strong supporting evidence

Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.

C

Contextual evidence

Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.

D

Signal-generating evidence

Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.

Tier and confidence answer different questions

Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.

Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.

peptide explorer

Structural visualization and provenance

Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.

Fully specified molecular identity

Molecular formula
C45H55N9O6
Molecular weight
817.9 g/mol
Exact identity / sequence notation
D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
Identity-defining modifications
  • D-Ala1
  • D-2-naphthylalanine2
  • D-Phe5
  • C-terminal amide
PubChem CID
6918245
InChIKey
HRNLPPBUBKMZMT-RDRUQFPZSA-N

Non-standard residues and stereochemistry are exact in notation, not inferred from the viewer.

Sources: NIH PubChem — Pralmorelin / GHRP-2 · reviewed 2026-09-17

Representative sequence-derived model
Structure source
Generated from this record's governed amino-acid sequence
Identifier
Not applicable — not a database structure
Method
Schematic layout ordered by residue position only; not a molecular-dynamics, homology, or fold prediction
Confidence / limitations
Illustrative only. Not physically accurate; carries no structural, binding-site, or activity meaning.
Provenance
WPF governed PeptideChemistry record
Retrieved / last reviewed
2026-09-17

This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.

Suggested citation

  • APA

    World Peptide Foundation. (n.d.). GHRP-2 — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 20, 2026.) https://www.worldpeptidefoundation.org/directory/ghrp-2

  • AMA / Vancouver

    World Peptide Foundation. GHRP-2 — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 20, 2026. https://www.worldpeptidefoundation.org/directory/ghrp-2